- Details
- In this episode of Kidney Cancer Today, Bradley McGregor joins Monty Pal and Jamie Landman to speak about the major practice-changing studies that have come out over the past year in the frontline setting and the evolution of therapy in the renal cell carcinoma space. Biographies: Bradley McGregor, MD, Clinical Director, Senior Physician, Instructor in Medicine, Lank Center for Genitourinary Oncol...
|
- Details
- Rana McKay and Monty Pal share in a discussion on the study design and results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation. Biographies: Rana R. McKay, MD, Medical Oncologist, Assistant Professor of Medicine, UC San Diego Health Sumanta Kumar Pal, MD Associate Clinical Profe...
|
- Details
- Shaan Dudani joins Monty Pal and Jaime Landman, sharing an overview of the First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium which was published this past August in European urology. Using the International Metastatic Renal-cell Carcinoma Database Consortium (IMDC) dataset, patient...
|
- Details
- Alicia Morgans and David Braun discuss his innovative research in metastatic kidney cancer which focuses on understanding and improving immunotherapies in kidney cancer. His work utilizes immunogenomic approaches to generate mechanisms of response and resistance to existing immunotherapies. He is working to develop novel immune-based treatments. David’s key talking points are driven from the thoug...
|
- Details
- Tian Zhang, MD and Monty Pal, MD review first-line therapy options for metastatic renal cell carcinoma (mRCC), including immunotherapy- based ipilimumab, nivolumab, pembrolizumab, axitinib, as well as avelumab/axitinib combinations and cabozantinib monotherapy. Tian continues focusing on achieving a complete response rate, and treating intermediate, poor-risk disease where she describes an excitin...
|
- Details
- Tian Zhang and Alicia Morgans discuss the three new approvals for the first line treatment of metastatic renal cell carcinoma, including cabozantinib with targeted agents, IO combinations with ipilimumab and nivolumab and now the recent approval of pembrolizumab plus axitinib. Dr. Zhang reviews the long-term follow-up from the CHECKMATE-214 study along with the CABOSUN data. The discussion conclud...
|
- Details
- Lauren Harshman, MD, Alicia Morgans, MD and Toni Choueiri, MD discuss combination therapy for the management of metastatic kidney cancer with the recent approval of pembrolizumab plus axitinib. The combination was approved for all patients regardless of risk category. This adds to the treatment armamentarium for metastatic kidney cancer with the already approved nivolumab plus ipilimumab regimen....
|
- Details
- Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...
|
- Details
- Rana McKay, MD reviews the evolving landscape for the frontline treatment of metastatic RCC. Historically, patients were treated with first-line TKIs although the paradigm has been shifting over the past two years including, VEGF targeted therapy with immunotherapy and IO-IO combinations. Dr. McKay reviews the data from KEYNOTE 426 with pembrolizumab plus axitinib which demonstrated a survival ben...
|
- Details
- Sandy Srinivas, MD discusses the frontline data from the KEYNOTE 426 trial comparing pembrolizumab plus axitinib to sunitinib monotherapy in clear cell kidney cancer. 800 patients were randomized and the combination demonstrated benefit across all three outcomes measured including response rates, PFS and overall survival. Dr. Srinivas believes the tolerability for pembrolizumab plus axitinib is mo...
|
